Clinical Trial Update: Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for fingolimod aimed at reducing interstitial fibrosis and tubular atrophy after kidney transplantation, with enrollment by invi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Graft Rejection
• Interstitial Fibrosis of Kidney
• Kidney Transplant Rejection
• Tubular Atrophy

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Interstitial Fibrosis, Kidney Transplant; Complications | Phase 2 | Status: ENROLLING_BY_INVITATION